Stay updated with breaking news from Drug Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus substantially reduced RSV lower respiratory tract...
First and only RSV preventive option authorised for use in China AstraZeneca and Sanofi's Beyfortus , a long-acting monoclonal...
The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. The statute sets a deadline of September 1, 2023 for the Secretary of Health and Human...
FDA approves Beyfortus™ to protect infants against RSV disease Beyfortus™ is the first monoclonal antibody approved to protect all infants through their first RSV seasonAcross all clinical...
AstraZeneca Nirsevimab unanimously recommended by FDA Advisory Committee